The Translational Advances in Stem Cells for Diabetes Symposium aims to promote research interaction and collaboration at the intersection of diabetes and stem cell biology. Its scope covers stem cell-derived pancreatic islets for cell therapy, the understanding of diabetes pathogenesis using stem cells, the establishment of clinically relevant iPSCs, and precision medicine in diabetes.
Chair’s Welcome Message I extend my warm welcome to all of you to the Translational Advances in Stem Cells for Diabetes Symposium, which is organized by the Steering Committee of QBRI-HSCI Agreement. This year’s symposium will bring together leaders and trainees from cutting-edge fields of stem cells and diabetes to spur research interaction and collaboration at the intersection of diabetes and stem cells. The event aims to enable participants to exchange new ideas and develop innovative approaches on potential treatments of diabetes using stem cells. I look forward to welcoming you! Dr. Essam M. Abdelalim Chair, Steering Committee of QBRI-HSCI Agreement Scientist at Qatar Biomedical Research Institute, HBKU Joint Assistant Professor, College of Health and Life Sciences, HBKU
Acting Executing Director’s Welcome Message On behalf of the Qatar Biomedical Research Institute (QBRI) at Hamad Bin Khalifa University (HBKU), I am delighted to welcome you to the Translational Advances in Stem Cells for Diabetes Symposium. As part of Qatar’s National Vision 2030, we have been diligently working in alignment with the National Strategy to Prevent Diabetes in Qatar. Through our collaboration with Harvard Stem Cell Institute (HSCI), we have been able to enhance QBRI’s capacity-building in stem cell technologies and perform stem cell research that increase our understanding of diabetes progression; paving the way to developing more effective treatments. We are grateful to the QBRI-HSCI Steering Committee and symposium participants, as your engagement provides essential practical knowledge and strengthens the network and connections with stem cell experts. We look forward to having you! Dr. Omar Albagha Acting Executive Director, Qatar Biomedical Research Institute, HBKU
Speakers Dr. Camillo Ricordi, Director of the Diabetes Research Institute (DRI) and the Cell Transplant Center, University of Miami (UM), USA Dr. Ramona Pop, Harvard Stem Cell Institute (HSCI), Harvard University, USA Dr. Adrian Teo, Principal Investigator, Institute of Molecular and Cell Biology, A*STAR, Singapore Dr. Chiara Cugno, Advanced Cell Therapy Core, Sidra Medicine, Qatar Dr. Abdul Badi Abou Samra, Qatar Metabolic Institute, HMC, Qatar Dr. Shahrad Taheri, Qatar Metabolic Institute, HMC, Qatar Dr. Paul John Thornalley, Diabetes Research Center (DRC), QBRI, Qatar Dr. Omar Albagha, Acting Executive Director, QBRI, Qatar Dr. Mohammed Bashir, HMC, Qatar. Dr. Essam M. Abdelalim, Diabetes Research Center (DRC), QBRI, Qatar Prof. Kenji Osafune, Head, Dept. of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan. Organizers Chair, Dr. Essam M. Abdelalim (Scientist, QBRI, HBKU) Member, Dr. Georges Nemer (Interim Dean and Professor, CHLS, HBKU) Member, Dr. Khalid Fakhro (Chief Research Officer, Sidra Medicine) Secretary, Mrs. Georgette Mansour (Project Lead, HBKU) Symposium Secretary, Ms. Amneh Tarkhan (Research Grant Specialist, QBRI, HBKU)
Abstract Submission The Steering Committee of QBRI-HSCI Agreement invites abstract submissions for a poster presentation within the following but not limited to the topics below:
Submission Guidelines The submission should contain a title, author(s), and the institutional or business affiliation of each author. The abstract should contain a full description of the topic, providing a background, objective, methods, results, and conclusion. Figures and tables should not be included in the abstract. The word count of the abstract should not exceed 500 words. All abstracts must be submitted electronically through the paper submission system in PDF format only. Abstracts will be selected based on their originality, timeliness, significance, relevance, and clarity of presentation. Deadline for abstract submission: 5 February 2023. Authors will be notified of a decision by 15 February 2023. Upon acceptance of an abstract, a minimum of one author must attend the symposium and deliver the presentation according to a scheduled date and time.Click here to register